scholarly journals Effect of Thyroglobulin Autoantibodies on the Metabolic Clearance of Serum Thyroglobulin

Thyroid ◽  
2018 ◽  
Vol 28 (3) ◽  
pp. 288-294 ◽  
Author(s):  
Francesco Latrofa ◽  
Debora Ricci ◽  
Sara Bottai ◽  
Federica Brozzi ◽  
Luca Chiovato ◽  
...  
Keyword(s):  
Metabolic Clearance ◽  
Serum Thyroglobulin ◽  
Thyroglobulin Autoantibodies

Differences in radioimmunoassay results for thyroglobulin that affect management of patients with thyroid cancer.

1984 ◽  
Vol 30 (1) ◽  
pp. 81-86 ◽  
Author(s):  
M F Bayer ◽  
I R McDougall
Keyword(s):  
Differentiated Thyroid Carcinoma ◽  
Medical Systems ◽  
Serum Thyroglobulin ◽  
Clinical Specimens ◽  
Inconclusive Result ◽  
Thyroglobulin Autoantibodies ◽  
Thyroglobulin Concentration ◽  
Positive Results ◽  
Disease Free ◽  
Good Agreement

Abstract We compared two commercial assays for measurement of serum thyroglobulin [Nuclear Medical Systems (NMS) and "CIS" (Damon Diagnostics)] with each other and with one developed at Stanford (J Clin Endocrinol Metab 49:557-564, 1979). The NMS assay is a competitive-binding RIA, the CIS and Stanford assays are two-site immunoradiometric assays. The kit standards varied in thyroglobulin concentration. The NMS standards differed in immunoreactivity from thyroglobulin in clinical specimens and from the other standards. Also, nonparallelism between standards and patients' sera in the NMS assay suggested a less-specific antiserum. Results by the CIS and Stanford assays correlated well (n = 120, r = 0.964), those by the NMS assay less strongly (n = 101, r = 0.855 vs CIS, r = 0.888 vs Stanford). Clinical evaluation in 50 patients treated for differentiated thyroid carcinoma (10 with metastases and 40 currently disease-free) indicated good agreement for positive results by the three assays. The CIS and the Stanford assay both gave high results (greater than or equal to 25 micrograms/L) in all 10 cases with metastases; the NMS RIA identified eight of these patients (thyroglobulin greater than or equal to 30 micrograms/L), but excluded two with anti-thyroglobulin autoantibodies. In subjects without disease, however, the percentage of undetectable thyroglobulin (negative result), as opposed to low measurable thyroglobulin (inconclusive result) varied considerably: 85% by CIS, 30% by NMS, and 75% by the Stanford assay.

Thyroglobulin autoantibodies before radioiodine ablation predict differentiated thyroid cancer outcome

2017 ◽  
Vol 55 (12) ◽  
Author(s):  
Pierpaolo Trimboli ◽  
Valentina Zilioli ◽  
Mauro Imperiali ◽  
Luca Giovanella
Keyword(s):  
Disease Free Survival ◽  
Differentiated Thyroid Carcinoma ◽  
Serum Thyroglobulin ◽  
Significant Drop ◽  
Risk Class ◽  
Radioiodine Ablation ◽  
Before And After ◽  
Thyroglobulin Autoantibodies ◽  
Cancer Outcome

AbstractBackground:Serum thyroglobulin (Tg) is essential to manage differentiated thyroid carcinoma (DTC). However, Tg determination is affected by circulating Tg antibodies (TgAb), and a role of TgAb as surrogate biomarker has been proposed. Here we evaluated the role of TgAb measured before and after radioiodine ablation (RRA) as potential predictors of prognosis.Methods:Patients treated since 2006 were screened. Cancers with structural relapse were defined as recurrent. Both Tg and TgAb were measured by immunoassays on the fully automated KryptorResults:A series of 215 DTC patients was enrolled, of whom 28.8% had positive preablation TgAb. Overall, 2.8% patients died by DTC and 11% recurred. High-risk class (p=0.004) and cancer relapse (p=0.007) occurred more frequently in positive TgAb, whereas better disease-free survival was observed in negative group (hazard ratio 2.59, p=0.01). Having positive preablation TgAb was significantly associated with risk to develop recurrence (odds ratio 3.57, p=0.004). Among positive TgAb subgroup, higher levels were recorded in recurrent cases (p=0.0001), and the most accurate preablation TgAb threshold was 107.5 IU/mL. When TgAb were measured at first follow-up, recurrence rate was significantly (p<0.0001) higher in persistently TgAb-positive patients (75%) than normalized ones (2.4%). At that time, the highest negative predictive value could be obtained when considering TgAb normalization (<33 IU/mL) or reduction by ≥36.4%.Conclusions:Positive TgAb before RRA indicates higher risk of poor prognosis, but their significant drop 6–12 months later could be considered a favorable factor.

Analytical and clinical performance of thyroglobulin autoantibody assays in thyroid cancer follow-up

2017 ◽  
Vol 55 (12) ◽  
Author(s):  
Waddah Katrangi ◽  
Stephan K.G. Grebe ◽  
Alicia Algeciras-Schimnich
Keyword(s):  
Thyroid Cancer ◽  
Clinical Performance ◽  
Reference Interval ◽  
Surrogate Markers ◽  
Roc Curve Analysis ◽  
Serum Thyroglobulin ◽  
Qualitative And Quantitative ◽  
Limit Of Quantitation ◽  
Thyroglobulin Autoantibodies

AbstractBackground:While thyroglobulin autoantibodies (TgAb) can result in false low serum thyroglobulin (Tg) immunoassay (IA) measurements, they might also be indicators of disease persistence/recurrence. Hence, accurate TgAb measurement, in addition to Tg quantification, is crucial for thyroid cancer monitoring. We compared the analytical and clinical performance of four commonly used TgAb IAs.Methods:We measured Tg by mass spectrometry (Tg-MS) and by four pairs of Tg and TgAb IAs (Beckman, Roche, Siemens, Thermo) in 576 samples. Limit of quantitation (LOQ) and manufacturers’ upper reference interval cut-off (URI) were used for comparisons. Clinical performance was assessed by receiving operator characteristics (ROC) curve analysis.Results:Quantitative and qualitative agreement between TgAb-IAs was moderate with RConclusions:TgAb-IAs show significant qualitative and quantitative differences. For 2 of the 4 TgAb-IAs, using the LOQ improves the detection of interfering TgAbs. All assays showed suboptimal clinical performance when used as surrogate markers of disease, with modest improvements when Tg and TgAb were combined.

scholarly journals MON-495 Influence of Lymphocytic Thyroiditis at Histology and Serum Thyroglobulin Autoantibodies on the Course of Papillary Thyroid Carcinoma

2020 ◽  
Vol 4 (Supplement_1) ◽  
Author(s):  
Nicola Viola ◽  
Laura Agate ◽  
Sonia Caprio ◽  
Debora Ricci ◽  
Alessandro Brancatella ◽  
...  
Keyword(s):  
Papillary Thyroid Carcinoma ◽  
Thyroid Carcinoma ◽  
Total Thyroidectomy ◽  
Whole Body ◽  
Thyroid Autoantibodies ◽  
Papillary Thyroid ◽  
Serum Thyroglobulin ◽  
Neck Ultrasound ◽  
Thyroglobulin Autoantibodies ◽  
Structural Disease

Abstract PURPOSE Papillary thyroid carcinoma (PTC) is frequently associated with diffuse lymphocytic thyoiditis (LT) at histology and serum autoantibodies to thyroglobulin (TgAb) and to thyroperoxidase (TPOAb). The influence of LT and thyroid autoantibodies on the prognosis of PTC is debated. We evaluated the clinical course of a large group of PTC patients according to the presence or absence of LT (LT+ and LT-) and thyroid autoantibodies. METHODS We evaluated 194 consecutive and non-selected PTC patients treated with total thyroidectomy plus ¹³¹I ablation between 2007 and 2009, followed for 7.2 years (mean). 72 patients had follicular variant of PTC, 97 classic, 16 tall cells and the remaining 9 others variants (solid or oxyphilic cells). LT was diagnosed in presence of &gt;10 lymphocytes/field (40x). At the time of ablation, all patients underwent measurement of Tg, TgAb and TPOAb, neck ultrasound and whole body scan. After ablation, patients underwent Tg (Beckman Coulter), TgAb and TPOAb (Tosoh) measurement and neck ultrasound (associated with other imaging if required) every 6-12 months. PTC was considered in remission according to the following criteria: un-stimulated Tg &lt;0.2 ng/mL or stimulated Tg &lt;1 ng/mL with TgAb &lt;8 IU/mL and no evidence of structural disease. PTC was considered as persistent when un-stimulated Tg was ≥0.2 ng/mL or stimulated Tg was ≥1 ng/mL, or when TgAb were ≥8 IU/mL, or there was evidence of structural disease. RESULTS LT was found in 47% of patients, with a F/M ratio of 6.6/1, and was associated with a hypoechoic pattern at thyroid ultrasound (p = 0.05). At the end of follow-up 44/194 (22.7%) had persistent disease. Among them, 17/72 (23.6%) were follicular, 19/97 (19.6%) classic, 6/16 (37.5%) tall cells and 2/9 (22.2%) other variants. The time to remission was longer in the LT+ compared to the LT- patients (19.5 vs 7.5 months) (median) (p &lt;0.001), in TgAb positive compared to TgAb negative patients (28.5 vs 7.5 months) (p &lt;0.001) and in TPOAb positive compared to TPOAb negative patients (28.0 vs 8.0 months) (p = 0.005). At multivariate analysis TgAb were the only independent factor influencing the time to remission (0.54; 0.35-0.83; HR and confidence interval) (p = 0.001). However, evaluating only the 111 TgAb negative patients, the time to remission (undetectable un-stimulated or stimulated Tg and no evidence of structural disease) was similar in the LT+ and LT- groups (8.0 months for both). At variance, in 83 TgAb positive patients the time to remission was longer in LT+ than in LT- patients (29.3 vs 13.0 months) (p=0.01). CONCLUSIONS The time to remission is longer in LT+ compared to LT- PTC patients treated with total thyroidectomy plus ¹³¹I ablation. This is due to the frequent association of LT with TgAb, because undetectable TgAb is required to define the remission of PTC. Indeed, coexistent LT does not influence the time to remission when the analysis is restricted to TgAb negative patients.

Sign in / Sign up

Export Citation Format

Share Document